We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Vigil Neuroscience Inc (VIGL) USD0.0001

Sell:$3.92 Buy:$3.96 Change: $0.03 (0.75%)
NASDAQ:0.63%
Market closed |  Prices as at close on 18 October 2024 | Switch to live prices |
Sell:$3.92
Buy:$3.96
Change: $0.03 (0.75%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 18 October 2024 | Switch to live prices |
Sell:$3.92
Buy:$3.96
Change: $0.03 (0.75%)
Market closed |  Prices as at close on 18 October 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.

Contact details

Address:
100 Forge Road, Suite 700
WATERTOWN
02472
United States
Telephone:
+1 (857) 2544445
Website:
https://www.vigilneuro.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VIGL
ISIN:
US92673K1088
Market cap:
$153.04 million
Shares in issue:
39.65 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Ivana Magovcevic-Liebisch
    President, Chief Executive Officer, Director
  • Jennifer Ziolkowski
    Chief Financial Officer
  • David Gray
    Chief Scientific Officer
  • Christopher Verni
    General Counsel
  • Petra Kaufmann
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.